11 - Bibliografia - 2ª Parte

184. LJEW, D.F.M., NG, C.S.A., YONG, Y.M., and RATNAM, S.S. Long-term effects of Depo- Provera on carbohydrate and lipid metabolism. Contraception 31(1):51-64. Jan. 1985.

185. LISKIN, L. and QUILLIN, W.F. Long-acting progestins-Promise and prospects Population Reports, Series K, No. 2. Baltimore, Johns Hopkins School of Public Health, Population Information Program, May 1983. 40 p.

186. LITTLEFIELD, J. (Margaret Sanger Center International) [Noristerat in Namibia] Personal communication, Mar. 4,1993 and Feb. 15,1995.

187. LUBIS, F. (Yayasan Kusuma Buana) [Injectables in Indonesia] Personal communication, DK. 7,1993.

188. LUBIS, F., FAJANS, P., and SIMMONS, R. Maintaining technical quality of am in the introduction of Cyclofern in a national family planning program: Findings from Indonesia, Contraception 49(5): 527-541. May 1994.

189. MAIN, A. and SATTERTHWAITE, W. Anaphylactic shock following an injection of depo- provera. [Letter to the editor] British journal of Family Planning 13(4): 135. Jan. 1988.

190. MAINWARING, R., HALES, H.A., STEVENSON, K., HATASAKA, H.H., POULSON, A.M., JONES, K.P., and PETERSON, C.M. Metabolic parameter, bleeding, and weight changes in U.S. women using progestin only contracep,tives. Contraception 51(3):149-153. Mar 1995.

191. MALAWI. NATIONAL STATISTICAL OFFICE (NSO). and MACRO INTERNATIONAL (MJ). DEMOGRAPHIC AND HEALTH SURVEYS. Malawi Demo- graphic and Health Survey 1992. Zomba, Malawi. and Calverton, Maryland, NSO. and MI, Jan. 1994. 221 p.

192. MALONE, K.E., DALING, J.R., and WEISS, N.S. Oral contraceptives in relation to breast cancer Epidemiologic Reviews 15(1): 80-97.1993.

193. MATI, J.K.G., AGGARWAL, V.P., and FRASER, R.B. A 3-year follow-up study of use of norethisterone oenanthate in Nairobi, Kenya. journal of Obstetrics and Gynaecology of Eastern and Central Africa IM: 73-76. Jun. 1982.

194. MATTSON, R.H., CRAMER, J.A., CALDWELL, ON., and SICONOLFI, B.C. Treatment of seizures with medroxyprogesterone acetate: Preliminary report. Neurology 34(9):1255-1258. Sep. 1984.

195. MAULDIN, W.P. and MILLER, VC. Contraceptive use and commodifty costs in developing countries, 1994-2005. New York, United Nations Population Fund, 1994. (Technical Report Nº 18) 67 p.

196. MAZIS, M., MORRIS, L.A., and GORDON, E. Patient attitudes about two forms of printed oral contraceptive information. Medial Care 16(12): 1045-1054. Dec. 1978.

197. MCCANN, M.F., LISKIN, L.S., PIOTROW, P.T., RINEHART, W., and FOX, G. Breast-feeding, fertility, and family planning. Population Reports, Series 1, No. 24. Baltimore, Johns Hopkins School of Public Health, Population Information Program, Mar. 1984 (Rev.) 52 p.

198. MCCARTHY, J. (Columbia University) [Injectables vs. other methods] Personal communication, Apr. 28,1995.

199. MCDANIEL, E.B. (McCormick Christian Hospital) [McCoornick Family Planning Program) Personal communication, May 1, 1995.

200. MCEWAN, I.A., GRIFFIN, M., FOTHERBY, K., and TRAYNER, I. Long-term use of depot-norethisterone enanthate: Effect on blood lipid fractions. Contraception 46(1): 49-60. Jul. 1992.

201. MCEWAN, J.A and GRIFFIN, M. Long-term use of depot-norethisterone enanthate: Effect on blood coagulation factors and menstrual bleeding patterns. Contraception 44(6):639-648. DK. 1991.

202. MCFARLANE, C.P., FRIEDMAN, J.S., MORRIS, L., and GOLDBERG, H.I. Contraceptive Prevalence Survey, Jamaica 1993: 3. Sexual experience, contraceptive practice and fertility. [Kingston], Jamaica, National Family Planning Board, Oct. 1994.131 p.

203. MCNEIL, B.J., PAUKER, S.G., SOX, H.C., Jr., and TVERSKY, A. On the elicitation of preferences (or alternative therapies. New England journal of Medicine 306(21): 1259-1262. May 27, 1982.

204. MCNEILL, E. (USAID) [AID distribution of DMPA] Personal communication, DK. 22,1994.

205. MEADE, C.W., CASARIN, L.P.M., DIAZ, M.A., AQUADO, A.G., ZACARIAS, L.S., HOUCK, S., DIETHELM, P. and ANNUS, J. A clinical study of norethisterone enanthate in rural Mexico. Studies in Family Planning 15(3): 143-148. May-Jun. 1984.

206. MEHAFFEY, A. (Family Planning Association/New Zealand) (injectable contraceptives) Personal communication, Apr 6,1995.

207. MELTON, L.J., 3rd, KAN, S.H., WAHNER, H.W., and RIGGS, B.L. Lifetime fracture risk: An approach to hip fracture risk assessment based on bone mineral density and age. Journal of Clinical Epidemiology 41(10):985-994.1988.

208. MENG, Y.-X., JIANG, H.-Y., CHEN, A.-I., LU, F.-Y., YANG, H., ZHANG, M.-Y, SHEN, K.-Y, SUN, D.-L., SHAO, Q.-X., and FOTHERBY, K. Hemostatic changes in women using a monthly injectable contraceptive for we year Contraception 42(4): 455-466. Oct. 1990.

209. MENG, Y.-X. and VIRUTAMASEN, P. Effect of norethisterone enanthate on endometrial bleeding and changes in coagulation function, ovarian hormones and endometrial histology in Thai women. Contraception 44(1): 73-82. Jul. 1991.

210. MIGALLOS, G.T. (Kabilikat) [Social marketing of injectables] Personal communication, Nº 11, 1994.

211. MIRZA. T. (ICDDR/Bangladesh) [Injectables] Personal communication, DK. 28,1994.

*212. MIRZA, T., BARKAT-E-KHUDA, ASHRAE, A., HUMAYUN, K., HAQUE, I., ALAM, 5., MOZUMDER, K., and RAHMAN, M. Doorstep delivery of injectable contraceptives in eight thanas: Key findings. In: Barlkat-e-Khuda, Mirza, T., and Ahmed, S., eds. Lessons learned on doorstep delivery of injectable contracep.tives: Workshop proceedings. Dhaka, International Centre for Diarrhoeal Disease Research, 1994. p. 25-41.

213. MOSTERT, W.P. Recent trends in fertility in South Africa. In, Mostert, W.P. and Lötter, J.M., eds. South Africa's demographic future. Pretoria, South Africa, Human Sciences Research Council, 1990. p. 63-73.

214. NACHTIGALL, M.J., SCHWARTZ, L.B., and OLIVE, D.L. Endometriosis. In. Scott, I.R., Disaia, P.J., Hammond, C.B., and Spellacy, W.N., eds. Danforth's Obstetrics and gynecology. 7th ed. Philadelphia, J.B. Lippincott, 1994. p. 757-769.

215. NAESSEN, T., OLSSON, S.-E., and GUDMUNDSON, J. Differential effects on bone density of progestogen-only methods for contraception in pre-menopausal women. Contraception 52:35--39.1995.

216. NAIROBI CITY COMMISSION (NCC). and POPULATION COUNCIL (PC). and PATHFINDER FUND (PF). A situation analysis of the Nairobi City Commission family planning clinics. Nairobi, NCC. PC. Pf, Dec. 1991. 44 p. (Mimeo)

217. NARKAVONNAKIT, T., BENNETT, T., and BALAKRISHNAN, T.R . Cntinuation of injectable contraceptives in Thailand. Studies in Family Planning 13(4): 99-105. Apr. 1982.

218. NATIONAL INSTITUTE FOR POPULATION RESEARCH AND TRAINING IMPORT). Bangladesh Demographic and Health Survey 1993-94: Preliminary report. Dhaka, Bangladesh. and Calverton, Maryland, NIPORT, and Mitra and Associates. and Macro International Inc., Jul. 1994. 37 p.

219. NDIAYE, 5., DIOUF, P.D., and AYAD, M. Enquête Démographique et de Sant' au Sénégal (ÉDS-II) 1992/93. [Demographic and Health Survey of Sénégal (EDS-11) 1992/93.] [FRE] Dakar, Senegal. and Calverton, Maryland, Senegal Ministry of Finance, Treasury and Planning. Division of Demographics and Statistics. and Macro International, Apr. 1994.284 p.

220. NEW ERA, IIDS, and VARG (NIV) JOINT VENTURE. Nepal fertility, family planning and health survey (NFHS, 1991): Main report. [Draft] 1992.192 p.

221. NEW ZEALAND CONTRACEPTION AND HEALTH STUDY GROUP. History of long-term use of depot-medroxyprogesterone acetate in patients with cervical dysplasia; case-control analysis nested in a Cohort study. Contraception 50(5):443-449. Nov. 1994.

222. NEW ZEALAND CONTRACEPTION AND HEALTH STUDY GROUP. Risk of cervical dysplasia in users of oral contraceptives, intrauterine devices or depot-rnedroxlprogesterone acetate. Contraception 50(5):431-441. Nov. 1994.

*223. NEWTON, J.R., DARCANGUES, C., and HALL, P.E. Once-a-month combined injectable contraceptives. journal of Obstetrics and Gynaecology 14(Suppl. 1); SI-S34. Mar. 1994.

224. NGALLABA, S., KAPIGA, S.H., RUYOBA, I., and BOERMA, I.T. Tanzania Demographic and Health Survey 1991-92. Dar es Salaam, Tanzania. and Columbia, Maryland, Tanzania Bureau of Statistics. and Macro International Inc., Jun. 1993. 324 p.

225. NIGERIA. FEDERAL MINISTRY OF HEALTH (NMOHI). PRIMARY HEALTH CARE UNIT. FAMILY HEALTH SERVICES PROJECT. and OBAFEMI AWOLOWO UNIVERSITY (OAU). OPERATIONS RESEARCH UNIT AND NETWORK. and POPULATION COUNCIL (PC) AFRICA OR/TA PROJECT. Nigeria:The family planning situation analysis study. (Lagos), Nigeria, NMOH. and Ile-Ife, Nigeria, OAU. and [Nairobi], PIC, (19921. 48 p.

*226. O'BRIEN, B. 'What are my chances doctor? A review of clinical risks. London, Office of Health Economics, Nov 1986. (Studies of Current Health Problems No. 84) 44 p.

227. OBERLE, M.W., ROSERO-BIXBY, L., IRWIN, K.L., FORTNEY, J.A., LEE, N.C., WHATLEY, A.S., and BONHOMME, M.G. Cervical cancer risk and use of depot-medroxyprogesterone acetate in Costa Rica. International journal of Epidemiology 17(4): 718- 723. DK. 1988.

228. ODDENS, E.J., VEMER, H.M., VISSER, AR, and KETTING, E. Contraception in Germany: A review. Advances in Contraception 9(2):105-116. Jun. 1993.

229. OWENS, R. (John Snow) [Logistics for injectables] Personal communication, Jan. 14,1994.

230. OYELOLA, O.O. Fasting plasma lipids, lipoproteins, and apolipoproteins in Nigerian women using combined oral and progestin-only injectable contraceptives. Contraception 47(5): 445-454. May 1993.

231. PALMER, S.M., SHERRILL, J., and MORRISON, J.C. Diseases of the blood. In: Danforth, D.N. and Scott, J.R., eds. Obstetrics and gynecology. 5th ed. Philadelphia, J.B. Lippincott, 1986. p. 531-538.

232. PARDTHAISONG, T. and GRAY, R. In utero exposure to steroid contraceptives and outcome of pregnancy. American Journal of Epidemiology 134(8): 795-803. Oct. 15,1991.

233. PARDTHAISONG, T. and GRAY, R.H. The return of fertility following discontinuation of oral contraceptives in Thailand. Fertility and Sterility 35(5): 532-534. May 1981.

234. PARDTHAISONG, T, GRAY, R.H., MCDANIEL, E.B., and CHANDACHAM, A. Steroid contraceptive use and pregnancy outcome Teratology 38(1): 51-58. Jul. 1988.

235. PARDTHAISONG, T., GRAY, R.H., and MCDANIEL, E.B. Return of fertility after discominuation of depot medroxyprogesterone acetate and Intra-uterine devices in northern Thailand. Lancet 1(8166):509-511. Mar. 8,1980.

236.PARDTHAISONG,T. Return of fertility after use of the injectable contraceptive Depo-Provera: Up-dated data analysis. Journal of Biosocial Science 16(1):23-34.1984.

237. PARDTHAISONG, T., YENCHIT, C., and GRAY, R. The long-term growth and development of children exposed to Depo-Provera during pregnancy or lactation. Contraception 45(4): 313-324. Apt. 1992.

238. PARIANI, S., HEER, D.M., and VAN ARSDOL, M.D., Jr. Does choice make a difference to contraceptive use? Evidence from East lava. Studies in Family Planning 22(6): 384-390. Nov.-Dec. 1991.

239. PARKIN, D.M., PISANI, P., and FERLAY, J. Estimates of the worldwide incidence of eighteen major cancers in 1985. International Journal of Cancer 54(4): 594-606. Jun. 19,1993.

240. PARVEEN, L., CHOWDHURY, A.Q., and CHOWDHURY, Z. Inject" contraception (medroxyprogesterone acetate) in rural Bangladesh. La" 2(8045):946-948. Nov. 5,1977.

241. PATTAWICHAIPORN, S. (Planned Parenthood Association of Thailand [Injectables in Thailand] Personal communication, Jun. 28,1993.

242. PAUL, C., SKEGG, D.C.G., SMEIJERS, I., and SPEARS, G.F.S. Contraceptive practice in New Zealand. New Zealand Medical Journal 101 (859). 809-813. Dec. 14,1988.

243. PAUL, C., SKEGG, D.C.G., and SPEARS, G.F.S. Depot medroxyprogesterone, (Depo-Provera) and risk of breast cancer. British Medical journal 299(6702): 759-762. Sep. 23, 1989.

244. PEARSON, C. (National Womens Health Network) [Talk with the FDA on DMPA] Personal communication, Feb. 13,1995.

245. PEREZ PALACIOS, G. (Mexico. Ministry of Health) [injectables in the Mexican family planning program] Personal communication, Jan. 27, 1994.

246. PERRY, S. (John Snow) [Logistics for injectables] Personal communication, Jan. 23, 1994.

247. PETERSON, L.S. Contraceptive use in the United States: 1982-90. Advance Data 260: 1 - 15. Feb. 14, 1995.

248. PHILIPPINES. DEPARTMENT OF HEALTH (DOH). DMPA., The injectable contraceptive. An information kit. [loose-leaf booklet] [Manila], DOH, 1994. 10 p.

249. PHILIPPINES. NATIONAL STATISTICS OFFICE (NSO). and MACRO INTERNATIONAL (MI). DEMOGRAPHIC AND HEALTH SURVEYS. National Demographic Survey 1993. Manila. and Calverton, Maryland, NSO. and MJ, May 1994. 228 p.

250. PHILIPS, M. The patient's right not to know. Johns Hopkins Magazine 46(5); 3.

251. PHILLIPS, J.F. A use study of contraceptive Introduction: Domiciliary DMPA services in rural Bangladesh. Presented at the Committee on Population National Academy of Sciences seminar on the Demographic and Programmatic Consequences of Contraceptive Innervations, Washington, D.C., Oct. 6-7,1988.32 p.

252. PLATA, S. and BACHMAN, G. (SOMARC) [Social marketing of injectables] Personal communication, Dec. 21, 1993.

253. POPULATION COUNCIL. First-year comparison of IUD and implant condition rates: Conditions for which percentages with condition were significantly higher for implant subjects. Table 21. Presented at public hearings on Norplant subdermal implants before the Fertility and Maternal Health Drugs Advisory Committee of the US Food and Drug Administration, Rockville, Maryland, Apr. 1989.

254. POPULATION COUNCIL. Operations research proposal: Lima office. 1993. 20 p. (Unpublished)

255. POPULATION COUNCIL (PC). INOPAL II. and FAMILY HEALTH INTER. NATIONAL (FHI). DMPA findings, Peru and Ecuador. Presented at the Co-op. erating Agencies meeting of the US Agency for International Development, Washington, D.C., Feb. 24,1994.2 p.

256. PRABHAVATHI, K. and SHESFADRI, A. Pattern of IUD use: A follow up of acceptors in Mysore. Journal of family Welfare 35(1) :3-16. Sep. 1988.

257. PROGRAM FOR APPROPRIATE TECHNOLOGY IN HEALTH (PATH).information for public health programs: Uniject prefilled syringe. Seattle, Washington, PATH, 119941. 8 p. (Mimeo)

258. PROGRAM FOR APPROPRIATE TECHNOLOGY IN HEALTH (PATH).SoloShot. Seattle, Washington, PATH, May 1993. 1 p. (Mimeo)

*259. PROGRAM FOR INTERNATIONAL TRAINING IN HEALTH (INTRAH).Guidelines for clinical procedures In family planning: A reference for trainers.2nd ed. Chapel Hill, North Carolina, INTRAH, 1992. 352 p.

260. PROPER, W. (John Snow) [Logistics for contraceptives] Personal communication, Feb. 13,1995.

261.QUINTONG, J.B. Follow-up study of DMPA acceptors 6-8 years (72 to 96 mos.) post- acceptancecavite, Aug. 1987. [Manila], Philippines. Aug. 1987.5 P. (Unpublished)

262. QUINTONG, ),B. (Philippines. Department of Health) [DMPA follow-up study results] Personal co Jul. 6, 1993.

263 . RAFIQUZ-ZAMAN, A.K.M. (Bangladesh ministry of Health and Family Welfare) [Injectables through Bangladesh government] Personal communication, Mar. 24,1994.

264. RAHMAN, S.S., JABEEN, S., MALAKAR, M., RAHMAN, S., KHATOON, I., AHMED, N., CHOWDHURY, S.M., HOLCK, S.E., BUSCA B., and AKHTER, H.Introduction of the injectable contraceptive NET-EN into family planning clinics in Bangladesh. Bulletin of the World Health Organization 63(4): 785-791.1985.

265. RAMAN-WILMS, L., TSENG, A.L.-I.,WIGHARDT, S., EINARSON, T.R., and KOREN, G. Fetal genital effects of first-trimester sex hormone exposure: A meta-analysis. Obstetrics and Gynecology 85(1):141-149. Jan. 1995.

266. REFENO, G., RABEZA, V, MBOUP, G., and SCHOEMAKER, J. Enquête Nationale Démographique et Sanitaire 1992. (National Demographic and Health Survey 1992.1 Antananarivo, Madagascar. and Calverton, Maryland, Madagascar National Center for Research on the Environment. and Macro International. Feb. 1994. 248 p.

*267. RILEY, A.P., STEWART, M.K., and CHAKRABORTY, 1. Program- and method-related determinants of first DMPA use duration in rural Bangladesh. Studies in Family Planning 25(5): 255-267. Sep.-Oct. 1994.

268. ROBEY, B., RUTSTEIN, S.G., NORRIS, L., and BLACKBURN, R. The reproductive revolution: New survey findings. Population Reports, Series M, Nº. 11. Baltimore, Johns Hopkins School of Public Health Population Information Program, Dec. 1992. 44 p.

269 . ROSENBLATT, KA. and THOMAS, D.B. Depot-medroxyprogesterone acetate (DMPA) and risk of liver cancer. International Journal of Cancer 49:182-185.1991.

270. SALEM, H.T., SALAH, M., ALY, M.Y., THABET, A.J., SHAABAN, M.M and FATHALLA, M.F. Acceptability of injectable contraceptives in Assiut. Egypt. Contraception 38(6): 697-710. Dec. 1988.

271. MG, G.W., SHAO, QX, GE, R.S., et al. A multicentred phase III comparative clinical trial of Mesigyna, Cyclolfern and Injectable No. 1 given montly by intramuscular injection Chinese women: 1. Contraceptive efficacy and side effects. Contraception 51 (3):167-183. Mar. 1995.

272. SANG, G.W., SHAD, Q.X,, GE, R S., et al. A multicentred phase III comparative clinical trial of Mesigyna, Cyclofem and Injectable No. I given monthly by Intramuscular injection to Chinese women: 2. The comparison of bleeding patterns. Contraception 51(3):185-192. Mar. 1995.

273. SCHAEFER, L. (JHPIEGO) [Infection prevention for injectables] Personal Communication, W. 20 and 22,1995.

274. SCHROCK, R. (Upjohn) [Allergic reactions to DMPA] Personal communication, Dec. 12,1994.

275. SCHROEDER, B. (Jaksonville, Florida Hospital) [Transcript of interview with DMPA user] Personal communication, Aug. 12,1993.

276 SCHWALLIE, P.C. and ASSENZO, J.R Contraceptive use-efficacy study utilizing medroxyprogesterone acetate administered as an Intramuscular injection once every 90 days. Fertility and Sterility 24(5): 331-339. May 1973.

277. SCHWALLIE, P.C. and ASSENZO, J.R. The effect of depo-medroxyprogesterone acetate an pituitary and ovarian function, and the return of fertility following its discontinuation: A review. Contraception 10(2): 181-202. Aug.1974.

278. SEVERY, L.J., THAPA, S., ASKEW, I., and GLOR, J. Menstrual experiences and beliefs: A multicountry study of relationships with fertility and fertility regulating methods. Women and Health 20(2):1-20.1993.

279. SHAABAN, M.M. Contraception with progestogens and progesterone during lactation. Journal of Steroid Biochemistry and Molecular Biology 40(4-6); 705-710.1991.

280. SHAARAWY, M. and EL-SHENOUFY, O. Serum glycocholic and glycochenodeoxycholic Kids in injectable contraceptives-Noristerat and depot provera users. Arab Journal of Laboratory Medicine 18(1): 171-177. Jan. 1992.

251. SIMMONS, FL, FAJANS, P., and LUBIS, F. Contraceptive introduction and to management of choice: The role of Cyclofem in Indonesia. Contraception 49(5): 509-525. May 1994.

282. SIMPSON, J.L. and PHILLIPS, O.P. Spermicides, hormonal contraception and congenital malformations. Advances in Contraception 6(3):141-167. 1990.

283. SKEGG, D.C.G. Monthly combined injectable contraceptives and neoplasia. Contraception 49(5): 435-439. May 1994.

*284. SKEGG, D.C.G., NOONAN, E.A., PAUL, C., SPEARS, G.F.S., MEIRIK, O., and THOMAS, D.B. Depot medroxyprogestarone acetate and breast cancer: A pooled analysis of the World Health Organization and New Zealand studies. Journal of the American medical Association 273(10): 799-804. Mat. 8,1995.

285. SOLHEIM, F. The assessment of quality of life in women treated with Depo-Provera in Sweden. In: Zambrano, D., ed. Depo-Provera (medroxyprogesterone acetate) for contraception: A current perspective of scientific, clinical and social issues. Proceedings of an international symposium held on 19-20 No, 1992, 2nd ed. Oxford, Oxford Clinical Communications, 1993. p. 61-72.

286. SOMBOONSUK, A., XUTO, N., GRAY, R.H., and GROSSMAN, P A. A field study of the choice and continuity of use of three contraceptive methods in a rural area of Thailand. Journal of Biosocial Science 10(2): 209-216. Apr. 1978.

287. SOWERS, M.R. and GALUSKA, D.A. Epidemiology of bone mass in premenopausal women. Epidemiologic Reviews 15(2): 374-398.1993.

288. SPICEHANDLER, J. and SIMMONS, R. Contraceptive introduction reconsidered : A review and conceptual framework. Geneva, World Health Organization, 1994. 34 p.

289. SPINELLI, A., GRANDOLFO, M., DONATI, S., and MEDDA, E. Family planning in Italy. Advances in Contraception 9(2):153-160. Jun. 1993.

290. STANFORD, J.L. Oral contraceptives and neoplasia of the ovary. Contraception 43(6): 543-556. Jun. 1991.

291. STANFORD, J.L. and THOMAS, D.B. Depot-medroxyprogesterone acetate (DMPA) and risk of epithelial ovarian cancer. International Journal of Cancer 49:191-195.1991.

292. STEELE VERME, C. and BENOIT, E. Family planning counseling. The international experience. Meeting report Istanbul, Turkey, Apr. 1992. New York, Association for Voluntary Surgical Contraception, 1993. 62 p.

213. STEINGLASS, R. (BASICS) [Infection prevention] Personal communication , Jul. 21,1995.

294. STEINGLASS, R., BOYD, D., GRABOWSKY, M, LAGHARI, A.G., KHAN, M.A., QAVI, A., and EVANS, P. Safety, effectiveness and ease of use of a non-reusable syringe in a developing country immunization programme. Butlain of the World Health Organization 73(1):57-63.1995.

295. SUYONO, H., SAFFITZ, G., and RIMON, J.G., 2nd. Indonesia: The Blue Circle Campaign. (Working Paper) Baltimore, Johns Hopkins University, Population Communication Services, Oct. 1989.12 p.

296. SZAREWSKI, A., HOLLINGWORTH, B., and GUILLEBAUD, J. Depot medrioxyprogesterone acetate and osteopoinsis: Monitor serum oestradiol con, centration in users. British medical Journal 308(6930): 717. Mar. 12,1994.

297. TANZANIA. MINISTRY OF HEALTH (TMOH). and POPULATION COUNCIL (PC). AFRICA OR/TA PROJECT, Tanzania: The family planning situation analysis study. Dar es Salam, Tanzania, TMOH. and Nairobi PC, 1992.45 p.

298. TAYLOR, W.E. (Planned Parenthood Association of Sierra Leone) [DMPA in Sierra Leone] Personal communication, Jun. 21,1993.

*299. TECHNICAL GUIDANCE WORKING GROUP. Recommendations for updating selected practices In contraceptive use: Results of a technical meeting. (Vol. 1) Chapel Hill, North Carolina, Program fix International Training in Health, Nov. 1994.130 p. (Mimeo)

300. THOMAS, D.B., MOLINA, R., CUEVAS, H.R., et al. Monthly injectable steroid contraceptives and cervical carcinoma. American Journal of Epidemiology 130(2): 237-247.1989.

*301. THOMAS, D.B. and NOONAN, E.A. Breast cancer and depot-medroxyprogesterone acetate: A multinational study. Lancet 338(8771): 833-838. Oct. 5, 1991.

302. THOMAS, D.B. and RAY, R.M. Depot-medroxyprogesterone acetate (DMPA) and risk of endometrial cancer. International Journal of Cancer 49: 186-190.1991.

303. THOMAS, D.B. and RAY, R.M. Depot-medroxyprogesterone acetate (DMPA) and risk of invasive squamous cell cervical cancer. Contraception 45: 299-312.1992.

304. THOMAS, D.B., YE, Z., RAY, R.M., and THE WHO COLLABORATIVE STUDY OF NEOPLASIA AND STEROID CONTRACEPTIVES. Cervical carcinoma in situ and use of depot-medroxyprogesterone, acetate (DMPA). Contraception 51(1): 25-31. Jan. 1995.

305. TIETJEN, L., CRONIN, W., and MCINTOSH, N. Infection prevention fix family planning service programs: A problem -solving reference manual. Durant, Oklahoma, Essential medial Information Systems, 1992. 254 p.

306. TIMYAN, J. (Population Services International) [Social marketing of injectables] Personal commumication, Dec. 8,1993.

307. TIPPING, S.L. Trip report: Nepal. Dec. 6-18, 1993. Washington, D.C., SOMARC/Futures Group, 1993.

308. TRELOAR, A.E., BOYNTON, R.E., BEHN, B.C., and BROWN, B.W. Variation of the human menstrual cycle through reproductive life. international journal of fertility 12(1, Pt.2): 77-126. Jan.-Mar. 1967.

309. TSAKOK, F.H.M., KOH, S., YUEN, R., and RATNAM, S.S. Coagulation studies in Asian women using injectable progestogen fix contraception. International journal of Gynaecology and Obstetrics 18(2):105-108. Sep.-Oct. 1980.

310. TURKEY. MINISTRY Of HEALTH (MOH). and HACETTEPE UNIVERSITY (HU). INSTITUTE OF POPULATION STUDIES. and DEMOGRAPHIC AND HEALTH SURVEYS (DHS). MACRO INTERNATIONAL. Turkey Demographic and Health Survey 1993. Ankara, Turkey. and Calverton, Maryland, MOH. and HU. and DHS, Oct. 1994. 247 p.

311. UNITED STATES. AGENCY FOR INTERNATIONAL DEVELOPMENT (AID). DMPA. Next steps. Washington, D.C., USAID, 19941.12 p. (Mimeo)

312. UPJOHN COMPANY (UC). Contraceptive confidence 3 months at a time. Kalamazoo, Michigan, UC, 1994.20 p.

313. UPJOHN COMPANY (UJ). Depo-Provera for contraception: Information for Public Board of Inquiry on Depo-Provera: Responses to the Board's questions. Kalamazoo, Michigan, Uj, Jun. 25,1982. 155 p.

314. VESSEY, M.P. Benefits and risks of combined oral contraceptives. Methods of Information in Medicine 32(3): 222-224. Apr. 1993.

315. VIRUTAMASEN, P. Long-acting injectable contraceptives-Current status. In: Palan, VT. and Nawi, M., eds. Recent advances in contraceptive technology: Proceedings of the seminar held on 14-20 Oct. 1987 in Chiang Mai, Thai land. London, International Planned Parenthood Federation, 1987. p. 86-92.

316. VIRUTAMASEN, P., WANGSUPHACHART, S., REINPRAYOON, D., KRIENGSINYOT, R., LEEPIPATPAIBOON, S., and GUA, C. Trabecular bone in long-term depot- medroxyprogesterone acetate users. Asia-Oceania Journal of Obstetrics and Gynaecology 20(3): 269-274. Sep. 1994.

317. VOIGT, L.F. and WEISS, N.S. Epidemiology of endometrial cancer, Cancer Treatment Research 49: 1-21. 1989.

318. WARNER-ROWE, R. (PATH) [Cyclofem] Personal communication, Oct. 14,1993, Apr. 20,1995, and Aug. 9,1995.

319. WEBB, S. and HOLMAN, D. A survey of contraceptive use and unplanned pregnancy in Perth, Western Australia. Australian Journal of Public Health 16(4): 382-386. Dec. 1992.

320. WEINER, E. and JOHANSSON, E.D.B. The influence of norethisterone, oenanthate on Marian function. Acta Endocrinologica 83(2): 386-392.Oct. 1976.

321. WEISBERG, E. The Depo-Provera controversy: Regulatory medical and social issues. In: Zambrano, D., ed. Depo-Provera (medroxyprpgesterone acetate) for contraception: A current perspective of scientific, clinical and social issues. Proceedings of an International symposium held on 19-20 Nov. 1992. 2nd ed. Oxford, Oxford Clinical Communications, 1993. p. 27. 38.

322. WEISZ. J., ROSS, G.T., and STOLLEY, P.D. Report of the Public Board of Inquiry on Depo-Provera. Oct. 26,1984.207 p. (Unpublished)

323. WERAWATGOOMPA, S., VAIVANIJKUL, B., LEEPIPATPAIBOON, S., CHANNIYOM, K., VIRUTAMASEN, P., and DUSITSIN, N. The effect of injectable norethisterone oenanthate on Marian hormones in Thai women. Contraception 21(3): 299-309. Mar. 1980.

324. WHELAN, E.M. Attitudes toward menstruation. Studies in Family Planning 6(4): 106-108, Apr. 1975.

325. WILLIAMS, E.M.I., JONES, L., VESSEY, M.P., and MCPHERSON, K. Short term increase in risk of breast cancer associated with full term pregnancy. British Medical journal 300(6724): 578-579. Mar. 3, 1990.

326. WILSON, J.G. and BRENT, R.L. Are female sex hormones teratogenic? American Journal of Obstetrics and Gynecology 141(5):567-580. Nov. 1, 1981. 327.

*327. WORLD HEALTH ORGANIZATION. A cross-cultural study of menstruation: Implications for contraceptive development and use. Studies in Family Planning 12(1): 3-16. Jan. 1981.

328. WORLD HEALTH ORGANIZATION (WHO). The effect of female sex hormones on fetal development and infant health. Geneva, WHO, 1981. (WHO Technical Report Series No. 657) 76 p.

329. WORLD HEALTH ORGANIZATION. Effects of hormonal contraceptives M breast milk composition and infant growth. Studies in Family Planning 19(6): 361-369. Nov.-Dec. 1988.

330. WORLD HEALTH ORGANIZATION. Facts about injectable contraceptives: Memorandum from a WHO meeting. Bulletin of the World Health Organization 60(2):199-210.1982.

*331. WORLD HEALTH ORGANIZATION. Facts about once-a-month injectable contraceptives: Memorandum hum a WHO meeting. Bulletin of the World Health Organization 71(6): 677-689.1993.

*332. WORLD HEALTH ORGANIZATION. Improving access to quality care in family planning: Medical criteria in selected methods Of contraception. (Draft) 11994,19951. 31 p.

*333. WORLD HEALTH ORGAN17ATION (WHO). Injectable contraceptives: Their role in family planning care. Geneva, WHO, 1990.117 p.

334. WORLD HEALTH ORGANIZATION. A multicentre comparative study of serum lipids and apolipoproteins in long-term users of DMPA and a control group of IUD users. Contraception 47(2):177-191. Feb. 1993.

335. WORLD HEALTH ORGANIZATION. A multi-centered pharmacokinetic, pharmacodynamic study of once-a-month injectable contraceptives, 1. Different doses of HRP1 12 and of depoprovera. Contraception 36(4): 441-457. Oct. 1987.

336. WORLD HEALTH ORGANIZATION. A multicentered Phase III comparative study of two hormonal contraceptive preparations given once-a-month by intramuscular injection: 1. Contraceptive efficacy and side effects. Contraception 37(1):1-20. Jan. 1988.

337. WORLD HEALTH ORGANIZATION. A multicentred Phase III comparative study of two hormonal contraceptive preparations given once-a-month by intramuscular injection. 2. The comparison of bleeding patterns. Contraception 40(5): 531-551. Nov. 1989.

338. WORLD HEALTH ORGANIZATION. A multicentred Phase III comparative clinical trial of depot-medroxyprogesterone acetate given three-montly at doses of 100 mg or 150mg: 1. Contraceptive efficacy and side effects. Contraception 34(3): 223-235. Sep. 1986.

339. WORLD HEALTH ORGANIZATION. A multicentred Phase III comparative clinical trial of depot-medroxyprogesterone acetate given three-monthly at doses of 100mg or 150mg: 2. The comparison of bleeding patterns. Contraception 35(6):591-610. Jun. 1987.

340. WORLD HEALTH ORGANIZATION. Multinational comparative clinical evaluation of two long-acting injectable contraceptive steroids: Norethisterone oenanthate and medroxyprogesterone acetate: 1. Use-effectiveness. Contraception 15(5):513-533. May 1977.

341. WORLD HEALTH ORGANIZATION. Multinational comparative clinical evaluation of two long-acting injectable contraceptive steroids: Norethisterone oenanthate and medroxyprogesterone acetate: 2. Bleeding patterns and side effects. Contraception 17(5): 395-406. May 1978.

342. WORLD HEALTH ORGANIZATION. Multinational comparative clinical trial of long-acting Injectable contraceptives: Norethisterone enanthate given in two dosage regimens and depot-medroxyprogesterone acetate Final report. Contraception 28(1):1-20. Jul. 1983.

343. WORLD HEALTH ORGANIZATION (WHO). The prevalence of anaernia in women: A tabulation of available information. (2nd ed.) Geneva, WHO, 1992. 100 P. (Mimeo)

344. WORLD HEALTH ORGANIZATION (WHO). Reducing the risk of unsafe injections in immunization programmes: The role of injection equipment. Geneva, WHO, 1994. (Logistics for Health Information Series 94.2 13 p.

345. WORLD HEALTH ORGANIZATION (WHO). Yamoussoukro declaration on the safety of injections. Geneva, WHO, 119941. 2 p.

346. WORLD HEALTH ORGANIZATION. SPECIAL PROGRAMME OF RE. SEARCH, DEVELOPMENT AND RESEARCH TRAINING IN HUMAN REPRODUCTION. Safety of the long-acting injectable contraceptive Depo-Provera. Oct. 30,1978. 7 p. (Unpublished)

347. WORLD HEALTH ORGANIZATION. TASK FORCE FOR EPIDEMIOLOGICAL RESEARCH ON REPRODUCTIVE HEALTH. Progestogen-only contraceptives during lactation: 1. Infant growth. Contraception 50(1): 35-53. Jul. 1994. 348. WORLD HEALTH ORGANIZATION. TASK FORCE FOR EPIDEMIOLOGICAL RESEARCH ON REPRODUCTIVE HEALTH. Progestog-only contraceptives during lactation: 2. Infant development. Contraception 50(1): 55-68. Jul. 1994.

349 WORLD HEALTH ORGANIZATION. TASK FORCE ON ORAL CONTRACEPTIVES. A randomized, double-blind study of six combined oral contraceptives. Contraception 25(3): 231-241. Man 1982.

350. WYATT, H.V. The popularity of injections in the Third World: Origins and consequences for poliomyelitis. Social Science and Medicine 19(9); 911-915.1984.

351. WYNN, R.M. Obstetrics and gynecology: The clinical core. 5th ed. Philadelphia, Lea & Febiger, 1992.373 p.

352. YASER, Y. (Turkish Family Health and Planning Foundation) [Social market ng of Depo-Provera] Personal communications, Jan. 31 and Nov. 14, 1 994

353. ZACEST, R., CUSHWAY A., HAINES, C., and COS, I.W. Hypersensitivity reaction to Depo-Provera. Medical Journal of Australia 1(1): 12. Jan. 9,1982.

354. ZACHARIAS, S., AGUILERA, E., JIMENEZ J., ASSENZO, J.R., and ZAARTU, J.A. The effects of hormonal and non-hormonal contraceptives on human lactation and on the re- establishment of fertility. International journal of Gynaecology and Obstetrics 25(Suppl.): 249- 255.1987.

355. ZAMBRANO, D., ed. Depo-provera (medroxyprogesterone acetate) for contraception: A current perspective of scientific, clinical and social issues. Proceedings of an international symposium held on 19-20 Nov. 1992. Oxford, England, Oxford Clinical Communications, 1993. 74 p.

356. ZAÑARTU, J., AGUILERA, E., ZACHARIAS, S., JIMENEZ J., and ASSENZO, J.R Effects of hormonal and nonhormonal contraceptives on human lactation and re-establishment of fertility. Presented at World Health Organization/National Academy of Sciences Workshop on Breastfeeding and fertility Regulation, Geneva, Feb. 17-24,1982. 21 p.

357. ZAÑARTU, J. and NAVARRO, C. Fertility inhibition by an injectable progestogen acting for 3 months: A clinical survey of 130 fertile women treated with norethisterone enanthate. Obstetrics and Gynecology 31(5): 627-633. May 1968.

358. ZIMBABWE. CENTRAL STATISTICAL OFFICE (CSO). and DEMOGRAPHIC AND HEALTH SURVEYS(DHS). MACRO INTERNATIONAL. Zimbabwe Demographic and Health Survey 1994: Preliminary report. Harare, Zimbabwe. and Calverton, Maryland, CSO. and DHS, Jan. 1995. 32 p.

359. ZIMMERMAN, A.W., HOLDEN, K.R., REITER, E.D., and DEKABAN, A.S. medroxyprogesterone acetate in the treatment of seizures associated with menstruation. Journal of Pediatrics 83(6): 959-963. Dec. 1973.

Adenda

360. BIERMAN, E.L. Atherosclerosis and other farms of arteriosclerosis. In: Isselbacher, K.J., Braunwald, E., Wilson,J.D., Martin, I.B. Fauci, A.S., and Kasper, D.L., eds. Harrison's principles of internal medicine. 13th ed. New York, McGraw-Hill, 1994. p. 1106-1116.

361. BROOKE, S. (PATH) [Uniject] Personal communication, August 9,1995. 362. GALLAGHER, ).C., KABLE, W.T., and GOLDGAR, D. Effect of progestin therapy on cortical and trabecular bone: Comparison with estrogen. American journal of Medicine 90(2):171-178. February 1991.

363. HABERLAND, M. (Planned Parenthood Federation of America) [Use of Depo-Provera by PPFA clients] Personal communication, June 6,1995.

364. HATCHER, P A., RINEHART, W., BLACKBURN, R, and GELLER, J. The essentials of contraceptive technology. Baltimore, Johns Hopkins Center for Communication Programs (forthcoming.

365. HUEZO, C. (IPPF) [injection schedule for NET EN] P-al communication, August 10, 1995.

366. MATLOMELO, S., MALIEHE, T., SAKOANE, 'M., and LEWIS, G. A study of contraceptive drop-outs in Lesotho: Using focus groups to determine causes of discontinuation. 1989. 43 p. (Unpublished)

367. MATTSON, R.H. and REBAR, R.W. Contraceptive methods for women with neurologic disorders. American journal of Obstetrics and Gynecology 168(6, Pt, 2): 2027-2032. June 1993.

368. MOGBISSI, K.S. and EVANS, T.N. Infertility. In: Danforth, D.N. and Scott, J.R., eds, Obstetrics and gynecology. 5th ed. Philadelphia J.B. Lippincon, 1986. p. 927-947.

369. SHARMA, J.B. Smoking may explain findings. [Letter] British medical Journal 3D8(6930): 717. March 12,1994.

370. TRUSSELL , J., HATCHER, R.A., CATES, W. Jr., STEWART, F.H., and KOST, K. Contraceptive failure in the United States: An update. Studies in Family Planning 21(1): 51-54. January-February 1990.

*371. WORLD HEALTH ORGANIZATION (WHO). and UNITED NATIONS CHILDREN'S FUND. Injections: Pledge for safety. [Blinder with text, VCR tape, and slides] Geneva, WHO, 1994.

ISSN 0887-0276


Population Reports is published by the Population Information Program, Center for Communication Programs, The Johns Hopkins School of Public Health, 111 Market Place, Suite 310, Baltimore, Maryland 21202-4012, USA

Palavras chave: of , population, planning, family planning, contraception, use, p , communication, family, information, contraceptive, k, long-term, may, jan, malawi, hopkins school public, long-term use, hopkins school, school public,